Gannon Steven's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Mar 8, 2024
- Accession no.
- 0000950170-24-028788
- Filed
- Mar 8, 2024
- Trade date
- Mar 7, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $601.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gannon StevenCIK 0001643085 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Common Shares | SSaleDisposed | −1,000 | $46.45 | −$46,450 | 14,000 | Direct | |
| Mar 7, 2024 | Common Shares | SSaleDisposed | −5,000 | $46.25 | −$231,250 | 9,000 | Direct | |
| Mar 7, 2024 | Common Shares | SSaleDisposed | −5,000 | $46.30 | −$231,500 | 4,000 | Direct | |
| Mar 7, 2024 | Common Shares | SSaleDisposed | −2,000 | $46.20 | −$92,400 | 2,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.